A 2022 Epilepsy Interaction Commentary Distinguished Midazolam Routes During Ritonavir Treatment

Historical interaction recommendations illustrate why route and persistence of enzyme inhibition matter in a medication timeline.

What the supplied source reports

The 2022 commentary explained potent CYP3A inhibition by ritonavir and its persistence while enzyme activity recovers. It distinguished buccal midazolam rescue from intravenous administration in monitored medical settings and discussed alternative rescue planning for patients receiving nirmatrelvir-ritonavir.

Limits of the evidence

This publication is expert guidance from its stated period, not a comparative trial or a current prescribing update. Its suggestions cannot replace assessment of the exact products, patient and clinical setting. An interaction mechanism predicts a concern but does not quantify the exposure in every individual.

Implications for forensic interpretation

For retrospective review, document antiviral doses and stop time, the benzodiazepine route and any monitoring or respiratory support. Do not assume that an interaction ends immediately when the last inhibitor dose is swallowed. The source supports a route-specific pharmacological explanation, while leaving actual concentration and clinical effect to the case evidence.

Source and related reading

Source reviewed: Using nirmatrelvir ritonavir in patients with epilepsy An update from the Israeli chapter of the Int (PMC9314867). Forensic applications above are interpretive analysis of the supplied publication.

Related reading: Diazepam Was Part of Treatment After Antipsychotic-Associated Movement Symptoms During Alcohol Withdrawal.